AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25795406 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin (1·2 mg/m² via central venous line over 24 h on day 1 of a 21 day treatment cycle)
Number of subjects: 76
Study 25795406 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 76
Study 23940307 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (titrated to 25 or 50 mg daily)
Number of subjects: 1663
Study 20886786 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep puncture at ST 25 with electric stimulation
Number of subjects: 95
Study 20886786 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow puncture at ST 25 with electric stimulation
Number of subjects: 95
Study 20886786 — intervention group
Group type: COMPARATOR
Intervention: Medication group (Duphalac)
Number of subjects: 95
Study 18186979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 30
Study 18186979 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 30
Study 17147493 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISPOT assay
Number of subjects: 0
Study 17147493 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS assay
Number of subjects: 0
Study 17147493 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk culture CTL
Number of subjects: 0
Study 17147493 — intervention group
Group type: EXPERIMENTAL
Intervention: MHC I tetramer staining
Number of subjects: 0
Study 17147493 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐gamma ELISPOT
Number of subjects: 0
Study 17147493 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐gamma intracellular cytokine staining
Number of subjects: 0
Study 14555263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (2 mg every 3 months) and calcium (1000 mg daily)
Number of subjects: 14
Study 14555263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (2 mg every 3 months) and calcium (1000 mg daily) with 700 IU vitamin D daily in the second year
Number of subjects: 14
Study 14555263 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment
Number of subjects: 14
Study 11078987 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary iodine concentration (UIC) measured in microg/l
Number of subjects: 412
Study 11078987 — intervention group
Group type: EXPERIMENTAL
Intervention: UIC in children and male adolescents
Number of subjects: 412
Study 11078987 — intervention group
Group type: COMPARATOR
Intervention: Comparison of UIC data with WHO criteria and previous non-randomized Swiss UIC data
Number of subjects: 412
Study 9097349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation in assist/control mode (nIPPV)
Number of subjects: 14
Study 9097349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal pressure support ventilation (nPSV)
Number of subjects: 14
Study 1316330 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg daily for 14 days
Number of subjects: 16
Study 2579953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40 peroperatively plus 0.5 g aspirin a day for 10 days
Number of subjects: 83
Study 2579953 — intervention group
Group type: COMPARATOR
Intervention: Heparin calcium 5000 iu subcutaneously plus dihydroergotamine (DHE) 0.5 mg intramuscularly for 10 days
Number of subjects: 83
Study 2579953 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran/aspirin
Number of subjects: 83
Study 2579953 — intervention group
Group type: COMPARATOR
Intervention: DHE/heparin
Number of subjects: 83
Study 31895884 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5% twice daily for 42 days
Number of subjects: 50
Study 31895884 — intervention group
Group type: COMPARATOR
Intervention: Thermal Pulsation Procedure (TPP)
Number of subjects: 50
Study 30396189 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Health Program (OHP)
Number of subjects: 65
Study 30396189 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Exercise Program (WEP)
Number of subjects: 65
Study 30396189 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 65
Study 26614104 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic Dilation (PD)
Number of subjects: 201
Study 26614104 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Heller Myotomy (LHM)
Number of subjects: 201
Study 24958410 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cardiopulmonary sonography with standard treatment
Number of subjects: 128
Study 24958410 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only (Control)
Number of subjects: 128
Study 22972968 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 16077
Study 22972968 — intervention group
Group type: COMPARATOR
Intervention: Comorbidities (congestive heart failure)
Number of subjects: 16077
Study 22972968 — intervention group
Group type: COMPARATOR
Intervention: Leg pain
Number of subjects: 16077
Study 22972968 — intervention group
Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 16077
Study 22972968 — intervention group
Group type: COMPARATOR
Intervention: Current smoking
Number of subjects: 16077
Study 22972968 — intervention group
Group type: COMPARATOR
Intervention: Time on study
Number of subjects: 16077
Study 20551833 — intervention group
Group type: EXPERIMENTAL
Intervention: IFA-AN
Number of subjects: 194
Study 20551833 — intervention group
Group type: EXPERIMENTAL
Intervention: IFA-VG
Number of subjects: 194
Study 18280438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin (RBX) 32 mg/day
Number of subjects: 20
Study 18280438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16007101 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 (150 microg/m2/day of Lenograstim starting on day 1)
Number of subjects: 240
Study 16007101 — intervention group
Group type: EXPERIMENTAL
Intervention: G5 (150 microg/m2/day of Lenograstim starting on day 5)
Number of subjects: 240
Study 16007101 — intervention group
Group type: COMPARATOR
Intervention: G0 (no Lenograstim)
Number of subjects: 240
Study 16007101 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 and G5
Number of subjects: 240
Study 14671611 — intervention group
Group type: COMPARATOR
Intervention: CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone)
Number of subjects: 0
Study 10831103 — intervention group
Group type: COMPARATOR
Intervention: 250-ppm-F NaF rinse
Number of subjects: 7
Study 10831103 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000-ppm-F NaF rinse
Number of subjects: 7
Study 10831103 — intervention group
Group type: EXPERIMENTAL
Intervention: 228-ppm-F two-solution rinse
Number of subjects: 7
Study 8795596 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (AH; 200 mg daily)
Number of subjects: 57
Study 8795596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 1321248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (5‐40mg/day, mean dose 11 mg/day)
Number of subjects: 56
Study 1321248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose trichlormethiazide (2.0‐4.0 mg/day, mean dose 2.2 mg/day)
Number of subjects: 56
Study 1321248 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril and low-dose trichlormethiazide
Number of subjects: 56
Study 6427483 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term mitomycin C instillation therapy
Number of subjects: 0
Study 6427483 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30891734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-target mean arterial pressure of 70-80 mm Hg
Number of subjects: 197
Study 30891734 — intervention group
Group type: COMPARATOR
Intervention: Low-target mean arterial pressure of 40-50 mm Hg
Number of subjects: 197
Study 30891734 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI-positive brain lesions
Number of subjects: 197
Study 28061840 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program based on a behavior change protocol
Number of subjects: 238
Study 28061840 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 238
Study 28061840 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment program
Number of subjects: 238
Study 27183343 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine (DCS)
Number of subjects: 0
Study 27183343 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam (ALP)
Number of subjects: 0
Study 27183343 — intervention group
Group type: COMPARATOR
Intervention: placebo (PBO)
Number of subjects: 0
Study 24251381 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone (DFP) 30 mg/kg/day
Number of subjects: 37
Study 24251381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 22105798 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 51
Study 22105798 — intervention group
Group type: COMPARATOR
Intervention: Carbomer gel
Number of subjects: 51
Study 19252205 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometry under MAT EO condition
Number of subjects: 21
Study 17703832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous epoetin-delta (ED)
Number of subjects: 752
Study 17703832 — intervention group
Group type: COMPARATOR
Intervention: Epoetin-alpha (EA)
Number of subjects: 752
Study 17703832 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-delta (ED) during open-label phase
Number of subjects: 752
Study 15066066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall-prevention program implemented by residential care staff using existing resources, including a fall-risk assessment tool and strategies to address identified risks.
Number of subjects: 628
Study 15066066 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 628
Study 15066066 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall-prevention program
Number of subjects: 628
Study 11549300 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified release dipyridamole (200 mg b.i.d. p.o.)
Number of subjects: 400
Study 11549300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 9476765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (FG) injections
Number of subjects: 127
Study 9476765 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic saline-epinephrine (HSE) injections
Number of subjects: 127
Study 7946231 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-door rehabilitation treatment
Number of subjects: 43
Study 7946231 — intervention group
Group type: COMPARATOR
Intervention: Standard locked-ward treatment
Number of subjects: 43
Study 3284483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins
Number of subjects: 46
Study 3284483 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 46
Study 29912782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac shock-wave therapy (CSWT) in addition to optimal medical treatment (OMT)
Number of subjects: 0
Study 29912782 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy with sham procedure (OMT+placebo)
Number of subjects: 0
Study 28938905 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg with sustained-release (SR) sarpogrelate 300 mg (Anplone®) once a day for six months
Number of subjects: 0
Study 28938905 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg with clopidogrel 75 mg once a day for six months
Number of subjects: 0
Study 25525820 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for trachomatous trichiasis (TT)
Number of subjects: 483
Study 24687169 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride (500 mg) twice daily for 4 months
Number of subjects: 380
Study 24687169 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 4 months
Number of subjects: 380
Study 22851564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice a day) plus gemcitabine (1,250 mg/m² on days 1 and 8) and cisplatin (75 mg/m² on day 1)
Number of subjects: 904
Study 22851564 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus gemcitabine (1,250 mg/m² on days 1 and 8) and cisplatin (75 mg/m² on day 1)
Number of subjects: 904
Study 22851564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (400 mg twice a day)
Number of subjects: 904
Study 19342529 — intervention group
Group type: EXPERIMENTAL
Intervention: ISBAR communication tool education (40 min session)
Number of subjects: 85
Study 19342529 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 85
Study 17296390 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (10 mg in 4 cc saline) via electromotive drug administration
Number of subjects: 42
Study 17296390 — intervention group
Group type: COMPARATOR
Intervention: Saline (4 cc) via electromotive drug administration
Number of subjects: 42
Study 15446646 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-management program (12 1-hr. sessions over 24 weeks)
Number of subjects: 20
Study 15446646 — intervention group
Group type: COMPARATOR
Intervention: Placebo program (anthropometric measurements and lectures on nutrition)
Number of subjects: 20
Study 11231393 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) staining
Number of subjects: 9
Study 11231393 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy with MB staining
Number of subjects: 9
Study 9732153 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day oral itraconazole (200 mg daily)
Number of subjects: 150
Study 9732153 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral fluconazole (150 mg)
Number of subjects: 150
Study 9732153 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-day intravaginal clotrimazole (100 mg daily)
Number of subjects: 150
Study 8973028 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation program combined with office intervention
Number of subjects: 0
Study 12283426 — intervention group
Group type: EXPERIMENTAL
Intervention: gemeprost 1 mg pessaries
Number of subjects: 50
Study 12283426 — intervention group
Group type: COMPARATOR
Intervention: PGE2 7.5 mg gel
Number of subjects: 50
Study 6244920 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (150 mg t.i.c.)
Number of subjects: 20
Study 6244920 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (150 mg t.i.c.) + Hydrochlorothiazide
Number of subjects: 20
Study 30389229 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (400 mg/d)
Number of subjects: 35
Study 30389229 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin therapy
Number of subjects: 35
Study 30389229 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 35
Study 28143495 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured SMBG with clinical review every 3 months
Number of subjects: 450
Study 28143495 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured SMBG with additional monthly telecare support from a trained study nurse
Number of subjects: 450
Study 28143495 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetes care
Number of subjects: 450
Study 28143495 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 450
Study 25929840 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care intervention package for depression (psychoeducation, activity scheduling, problem solving treatment, and medication for severe depression)
Number of subjects: 234
Study 25929840 — intervention group
Group type: COMPARATOR
Intervention: Care as usual with enhanced training on depression diagnosis and management
Number of subjects: 234
Study 25929840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention and control groups
Number of subjects: 234
Study 25961613 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer (GD)
Number of subjects: 20
Study 25961613 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Comfort Bond + Desensitizer (GCBD)
Number of subjects: 20
Study 25961613 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Universal (SBU)
Number of subjects: 20
Study 23440432 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI at 3T
Number of subjects: 23
Study 23440432 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter angiography (CCA)
Number of subjects: 23
Study 20824373 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt (EPCS)
Number of subjects: 211
Study 20824373 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy (EST)
Number of subjects: 211
Study 18053019 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 50 microg via MDDPI
Number of subjects: 436
Study 18053019 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 100 microg via MDDPI
Number of subjects: 436
Study 18053019 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 200 microg via MDDPI
Number of subjects: 436
Study 18053019 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg via MDDPI
Number of subjects: 436
Study 18053019 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol 400 microg via SDDPI
Number of subjects: 436
Study 18053019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study 17109282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular rt‐PA treatment
Number of subjects: 0
Study 17109282 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 12698113 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Analgesia (PCA)
Number of subjects: 74
Study 12698113 — intervention group
Group type: COMPARATOR
Intervention: Patient-Controlled Epidural Analgesia (PCEA)
Number of subjects: 74
Study 10700419 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA testing using Hybrid Capture II (HCII) assay
Number of subjects: 642
Study 10700419 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA testing using Polymerase Chain Reaction (PCR) assays
Number of subjects: 642
Study 9682530 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression instructions
Number of subjects: 72
Study 9682530 — intervention group
Group type: COMPARATOR
Intervention: Nonsuppression instructions
Number of subjects: 72
Study 9682530 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent film
Number of subjects: 72
Study 9682530 — intervention group
Group type: COMPARATOR
Intervention: Humorous film
Number of subjects: 72
Study 9682530 — intervention group
Group type: COMPARATOR
Intervention: Neutral film
Number of subjects: 72
Study 7996391 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral doses of (+)-sotalol 50, 100, 200, and 300 mg
Number of subjects: 0
Study 7996391 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated oral doses of (+)-sotalol 200 mg twice daily for 6.5 days
Number of subjects: 0
Study 7996391 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous doses of (+)-sotalol 1.0 and 1.5 mg kg-1
Number of subjects: 0
Study 3069682 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (200 mg twice a day)
Number of subjects: 10
Study 3069682 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg twice a day)
Number of subjects: 10
Study 3069682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29397250 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite cartilage perichondrium island (CCPI) graft
Number of subjects: 168
Study 29397250 — intervention group
Group type: COMPARATOR
Intervention: Temporalis fascia graft
Number of subjects: 168
Study 27748235 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal zinc supplementation during pregnancy
Number of subjects: 242
Study 27748235 — intervention group
Group type: COMPARATOR
Intervention: Iron+folic acid without zinc (Control)
Number of subjects: 242
Study 26166637 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hFSH (Gonal F®) 150 IU subcutaneously three times a week for 3 months
Number of subjects: 82
Study 26166637 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 82
Study 23823132 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 29
Study 23823132 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 29
Study 21659889 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance circuit (HRC) training
Number of subjects: 33
Study 21659889 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional strength (TS) training
Number of subjects: 33
Study 21659889 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 18606983 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg orally once daily on days 1 to 21, every 28 days, for 52 weeks
Number of subjects: 49
Study 18606983 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg orally
Number of subjects: 49
Study 17641543 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA) 300 or 150 microg depending on hemoglobin concentration
Number of subjects: 221
Study 17641543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 17641543 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa (DA)
Number of subjects: 221
Study 14989559 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 51
Study 14989559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 11053506 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 15832
Study 11053506 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 15832
Study 11053506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15832
Study 9469655 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating 3 Hz magnetic field (induction 0.1 mT) applied for 20 min
Number of subjects: 62
Study 9469655 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 62
Study 7912085 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 lymphocyte count measurements
Number of subjects: 851
Study 7912085 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in individual CD4 count
Number of subjects: 851